The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
Open accessAbstract
The 11(th) St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor (ER) expression is considered sufficient to justify the use of endocrine adjuvant therapy in almost all patients. Overexpression or amplification of HER2 by standard criteria is an indication for anti-HER2 therapy for all but the very lowest risk invasive tumours. The corollary is that ER and HER2 must be reliably and accurately measured. Indications for cytotoxic adjuvant therapy were refined, acknowledging the role of risk factors with the caveat that risk per se is not a target. Proliferation markers, including those identified in multigene array analyses, were recognised as important in this regard. The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Self-citationTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Endogenous human microRNAs that suppress breast cancer metastasis
Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., & Massagué, J. (2008) · Nature · doi:10.1038/nature06487 · Cited by 1,857
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.-H., Diebel, M. E., Monville, F., Dutcher, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2741 · Cited by 1,173
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
Self-citationEndocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983 · cited 1×
“steroid receptor cistrome, these studies have identified FOXA1 as an important component [8, 9].”
BackgroundRottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm271 · Cited by 944
Self-citation(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schütz, F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2124 · Cited by 891
Smith, B. D., Arthur, D. W., Buchholz, T. A., Haffty, B. G., Hahn, C. A., Hardenbergh, P. H., Julian, T. B., Marks, L. B., Todor, D. A., Vicini, F. A., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.02.031 · Cited by 872
Virtual and biomolecular screening converge on a selective agonist for GPR30
Bologa, C. G., Revankar, C. M., Young, S. M., Edwards, B. S., Arterburn, J. B., Kiselyov, A. S., Parker, M. A., Tkachenko, S. E., Savchuck, N. P., Sklar, L. A., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio775 · Cited by 818
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer
Ivshina, A. V., George, J., Senko, O., Mow, B., Putti, T. C., Smeds, J., Lindahl, T., Pawitan, Y., Hall, P., Nordgren, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4414 · Cited by 752
Estrogen Signaling through the Transmembrane G Protein–Coupled Receptor GPR30
Prossnitz, E. R., Arterburn, J. B., Smith, H. O., Oprea, T. I., Sklar, L. A., & Hathaway, H. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100518 · Cited by 590
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., Chan, A., Mackey, J., Liu, M., Pinter, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-62 · Cited by 553
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., Aragaki, A. K., Ockene, J. K., Lane, D. S., Sarto, G. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807684 · Cited by 472
Xing, Y., Foy, M., Cox, D. D., Kuerer, H. M., Hunt, K. K., & Cormier, J. N. (2006) · Journal of British Surgery · doi:10.1002/bjs.5209 · Cited by 402
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393
Viale, G., Giobbie-Hurder, A., Regan, M. M., Coates, A. S., Mastropasqua, M. G., Dell'Orto, P., Maiorano, E., MacGrogan, G., Braye, S. G., Öhlschlegel, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.0829 · Cited by 340
Self-citationDunne, C., Burke, J. P., Morrow, M., & Kell, M. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5182 · Cited by 321
Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., & Gelmon, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8659 · Cited by 301
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4789 · Cited by 293
Self-citationDowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 267
TAILORx: Trial Assigning Individualized Options for Treatment (Rx)
Sparano, J. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.051 · Cited by 262
Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0962 · Cited by 259
Self-citationGene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Bogaerts, J., Cardoso, F., Buyse, M., Braga, S., Loi, S., Harrison, J. A., Bines, J., Mook, S., Decker, N., Ravdin, P., et al. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0591 · Cited by 237
Ignatiadis, M., Kallergi, G., Ntoulia, M., Perraki, M., Apostolaki, S., Kafousi, M., Chlouverakis, G., Stathopoulos, E., Lianidou, E., Georgoulias, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4758 · Cited by 229
Jalava, P., Kuopio, T., Juntti‐Patinen, L., Kotkansalo, T., Kronqvist, P., & Collan, Y. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02402.x · Cited by 169
Unique ERα Cistromes Control Cell Type-Specific Gene Regulation
Krum, S. A., Miranda‐Carboni, G. A., Lupien, M., Eeckhoute, J., Carroll, J. S., & Brown, M. A. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0100 · Cited by 141
Survival and prognostic factors in BRCA1-associated breast cancer
Brekelmans, C. T. M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H. T., Tilanus‐Linthorst, M. M. A., Bartels, C. C. M., Kriege, M., van Geel, A. N., Crépin, C., Blom, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 137
Kyndi, M., Overgaard, M., Nielsen, H. M., Sørensen, F. B., Knudsen, H., & Overgaard, J. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.04.014 · Cited by 115
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga, J. M., Zambetti, M., Llombart‐Cussac, A., Manikhas, G., Kubista, E., Steger, G. G., Makhson, A. N., Tjulandin, S., Ludwig, H., Verrill, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2646 · Cited by 113
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy
Colleoni, M. A., Viale, G., Zahrieh, D., Bottiglieri, L., Gelber, R. D., Veronesi, P., Balduzzi, A., Torrisi, R., Luini, A., Intra, M., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm509 · Cited by 107
Self-citationAesöy, R., Sanchez, B. C., Norum, J. H., Lewensohn, R., Viktorsson, K., & Linderholm, B. K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2172 · Cited by 105
Kraus-Tiefenbacher, U., Bauer, L., Scheda, A., Schoeber, C., Schaefer, J., Steil, V., & Wenz, F. K. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-178 · Cited by 104
Molecular imaging of breast cancer
Munnink, T. H. O., Nagengast, W. B., Brouwers, A. H., Schröder, C. P., Hospers, G. A. P., Hooge, M. N. L.-D., van der Wall, E., van Diest, P. J., & de Vries, E. G. E. (2009) · The Breast · doi:10.1016/s0960-9776(09)70276-0 · Cited by 99
Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long-Term Follow-up
Kreike, B., Hart, A. A. M., van de Velde, T., Borger, J. H., Peterse, H. L., Rutgers, E. J. T., Bartelink, H. G. M. M., & van de Vijver, M. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.029 · Cited by 97
Eremin, O., Walker, M. B., Simpson, E., Heys, S. D., Ah-See, A. K., Hutcheon, A. W., Ogston, K. N., Sarkar, T. K., Segar, A., & Walker, L. G. (2008) · The Breast · doi:10.1016/j.breast.2008.09.002 · Cited by 71
Lewis-Wambi, J. S., Kim, H. R., Wambi, C. O., Patel, R. R., Pyle, J. R., Klein–Szanto, A. J., & Jordan, V. C. (2008) · Breast Cancer Research · doi:10.1186/bcr2208 · Cited by 67
Adjuvant therapy of triple negative breast cancer
Perez, E. A., Moreno‐Aspitia, A., Thompson, E. A., & Andorfer, C. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0736-z · Cited by 56
Seruga, B., & Tannock, I. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5594 · Cited by 53 · cited 1×
“Recent results from trials continue to support the benefit of aromatase inhibitors in postmenopausal women with receptor-positive breast cancer [54, 55], though others have questioned the extent of benefit [56].”
ResultEstrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen
NTUKIDEM, N., Nguyen, A., Stearns, V., Rehman, M., Schott, A. F., Skaar, T. C., Jin, Y., Blanche, P. J., Li, L., Lemler, S. M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100343 · Cited by 45
von Minckwitz, G., Kaufmann, M., Kümmel, S., Fasching, P. A., EIERMANN, W., Blohmer, J., Costa, S., Loibl, S., Dietmar, V., & Untch, M. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-79 · Cited by 37
PET Imaging of Steroid Receptor Expression in Breast and Prostate Cancer
Hospers, G. A. P., Helmond, F. A., de Vries, E. F. J., Dierckx, R., & de Vries, E. F. J. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404362 · Cited by 30
Gianni, L., Goldhirsch, A., Gelber, R. D., de Azambuja, E., Procter, M. J., Untch, M., Smith, I. E., Jackisch, C., Cameron, D., Muehlbauer, S., et al. (2009) · The Breast · doi:10.1016/s0960-9776(09)70033-5 · Cited by 23
Self-citationHiggins, M. J., & Davidson, N. E. (2008) · Current Oncology Reports · doi:10.1007/s11912-009-0008-4 · Cited by 16
Viale, G. (2009) · The Breast · doi:10.1016/s0960-9776(09)70269-3 · Cited by 11
The follow-up of women at high risk for breast cancer relapse
Smith, I. E., & Banerjee, S. N. (2009) · The Breast · doi:10.1016/s0960-9776(09)70277-2 · Cited by 1
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Self-citationEarly Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Giuliano, A. E. (2011) · JAMA · doi:10.1001/jama.2011.90 · Cited by 2,942
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Metadata
- Authors
- Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 20
- Issue
- 8
- Pages
- 1319-1329
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2155803397
- Cited by
- 1,374
- References
- 63
- FWCI
- 57.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.